The future of the oral pharmacotherapy of male erectile dysfunction: things to come.
The convincing clinical data on the use of the orally active phosphodiesterase inhibitors sildenafil, vardenafil and tadalafil for the treatment of male erectile dysfunction have boosted research activities on the physiology of the male erectile mechanism. This included both peripheral intracellular signal transduction in the corpus cavernosum as well as central brain and spinal cord pathways controlling penile erection. This work provided the basis for the development and introduction of several new therapeutic modalities into the management of erectile dysfunction, some of which are already offered to the patients. As the concept of 'taking a pill' as a cure for an illness or the relief of symptoms of a disease has become widely accepted by the consumers, the pharmacologic treatment of erectile dysfunction has primarily focussed on selective, orally available drugs acting by influencing intracellular or central regulatory mechanisms, combining a high response rate and the advantage of an on-demand intake. These agents are regarded as more efficacious, and have a faster onset of drug action in the target tissue and an improved effect to side-effect ratio. The purpose of this review is to describe the major novel and evolving pharmacologic advances in the field of oral pharmacotherapy for the treatment of male erectile dysfunction.
Uckert
Stefan
S
Hannover Medical School, Department of Urology, 30625 Hannover, Germany. sue_de_99@yahoo.de
Mayer
Margit E
ME
Stief
Christian G
CG
Jonas
Udo
U
D000284:Administration, Oral; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005544:Forecasting; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage; D014665:Vasodilator Agents / Q000008:administration & dosage
D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents